Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Devlin

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Blood Advances|June 28, 2023
Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantationRoni Tamari, Michael Scordo, Binni M Kunvarjee, et al.
The Lancet. Haematology|May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Blood Advances|October 1, 2020
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapiesDavid Sermer, Connie Batlevi, M Lia Palomba, et al.
Research Square|July 16, 2024
Calibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell LymphomaJae Park, M Lia Palomba, Karlo Perica, et al.
Transplantation and Cellular Therapy|March 1, 2026
Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-cell Therapy in Large B-Cell LymphomaMarina Gomez-Llobell, Roni Shouval, Samantha Brown, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
Targetable treatment resistance in thyroid cancer with clonal hematopoiesisVera Tiedje, Pablo Sánchez Vela, Julie L Yang, et al.
Blood Advances|September 10, 2021
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCTRoni Shouval, Joshua A Fein, Christina Cho, et al.
American Journal of Hematology|October 17, 2022
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemiaMaximilian Stahl, Andriy Derkach, Noushin Farnoud, et al.
The New England Journal of Medicine|September 10, 2015
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell LeukemiaEnrico Tiacci, Jae H Park, Luca De Carolis, et al.
Blood Advances|October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemiaYannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Blood Advances|June 28, 2023
Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantationRoni Tamari, Michael Scordo, Binni M Kunvarjee, et al.
The Lancet. Haematology|May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Blood Advances|October 1, 2020
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapiesDavid Sermer, Connie Batlevi, M Lia Palomba, et al.
Research Square|July 16, 2024
Calibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell LymphomaJae Park, M Lia Palomba, Karlo Perica, et al.
Transplantation and Cellular Therapy|March 1, 2026
Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-cell Therapy in Large B-Cell LymphomaMarina Gomez-Llobell, Roni Shouval, Samantha Brown, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
Targetable treatment resistance in thyroid cancer with clonal hematopoiesisVera Tiedje, Pablo Sánchez Vela, Julie L Yang, et al.
Blood Advances|September 10, 2021
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCTRoni Shouval, Joshua A Fein, Christina Cho, et al.
American Journal of Hematology|October 17, 2022
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemiaMaximilian Stahl, Andriy Derkach, Noushin Farnoud, et al.
The New England Journal of Medicine|September 10, 2015
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell LeukemiaEnrico Tiacci, Jae H Park, Luca De Carolis, et al.
Blood Advances|October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemiaYannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Pageof 8